Bob Geng

928 total citations
52 papers, 492 citations indexed

About

Bob Geng is a scholar working on Physiology, Immunology and Allergy and Dermatology. According to data from OpenAlex, Bob Geng has authored 52 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Physiology, 19 papers in Immunology and Allergy and 18 papers in Dermatology. Recurrent topics in Bob Geng's work include Asthma and respiratory diseases (19 papers), Dermatology and Skin Diseases (14 papers) and Allergic Rhinitis and Sensitization (13 papers). Bob Geng is often cited by papers focused on Asthma and respiratory diseases (19 papers), Dermatology and Skin Diseases (14 papers) and Allergic Rhinitis and Sensitization (13 papers). Bob Geng collaborates with scholars based in United States, United Kingdom and Canada. Bob Geng's co-authors include Marc A. Riedl, Eric Bradford, Masanori Ikeda, Jonathan Steinfeld, Steven W. Yancey, Robert G. Price, Sydney Leibel, Atul Gupta, Edward S. Schulman and D. William Cameron and has published in prestigious journals such as Scientific Reports, Journal of Allergy and Clinical Immunology and Frontiers in Immunology.

In The Last Decade

Bob Geng

49 papers receiving 474 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bob Geng United States 14 179 142 127 111 88 52 492
Denisa Ferastraoaru United States 11 124 0.7× 129 0.9× 90 0.7× 149 1.3× 103 1.2× 37 504
Andrew J. MacGinnitie United States 14 152 0.8× 147 1.0× 68 0.5× 302 2.7× 88 1.0× 40 643
Rémi Gagnon Canada 13 235 1.3× 63 0.4× 71 0.6× 281 2.5× 135 1.5× 35 550
Saira Z. Sheikh United States 11 160 0.9× 218 1.5× 55 0.4× 326 2.9× 51 0.6× 44 719
Francesca Saretta Italy 14 132 0.7× 113 0.8× 69 0.5× 229 2.1× 145 1.6× 54 690
Ramit Maoz‐Segal Israel 9 41 0.2× 113 0.8× 25 0.2× 84 0.8× 40 0.5× 22 489
B Z Garty Israel 11 66 0.4× 89 0.6× 60 0.5× 93 0.8× 24 0.3× 20 436
Ori Toker Israel 11 43 0.2× 118 0.8× 98 0.8× 32 0.3× 21 0.2× 30 384
Giacomo Malipiero Italy 12 104 0.6× 77 0.5× 86 0.7× 39 0.4× 13 0.1× 18 406
Inderpal Randhawa United States 10 87 0.5× 26 0.2× 119 0.9× 47 0.4× 21 0.2× 38 287

Countries citing papers authored by Bob Geng

Since Specialization
Citations

This map shows the geographic impact of Bob Geng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bob Geng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bob Geng more than expected).

Fields of papers citing papers by Bob Geng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bob Geng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bob Geng. The network helps show where Bob Geng may publish in the future.

Co-authorship network of co-authors of Bob Geng

This figure shows the co-authorship network connecting the top 25 collaborators of Bob Geng. A scholar is included among the top collaborators of Bob Geng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bob Geng. Bob Geng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cork, Michael J., Mette Deleuran, Bob Geng, et al.. (2025). Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age. The Journal of Allergy and Clinical Immunology In Practice. 13(5). 1164–1175.e2. 3 indexed citations
2.
3.
Stein‐Gold, Linda, Peter Lio, Raj Chovatiya, et al.. (2025). Key Treatment Attributes and Preferences of Allergists and Dermatologists for Moderate-To-Severe Atopic Dermatitis: Results from a US-Based Real-World, Cross-Sectional Study. Journal of Allergy and Clinical Immunology. 155(2). AB209–AB209. 1 indexed citations
4.
Guttman‐Yassky, Emma, et al.. (2025). 63485 Efficacy of Abrocitinib in Patients Based on Prior Biologic Treatment History: A Post Hoc Analysis of JADE MONO-1, JADE MONO-2, and JADE REGIMEN. Journal of the American Academy of Dermatology. 93(3). AB190–AB190.
5.
Geng, Bob, et al.. (2024). Multidisciplinary atopic dermatitis program: A novel approach to managing difficult‐to‐control atopic dermatitis patients. Pediatric Dermatology. 41(2). 210–214. 1 indexed citations
6.
Paller, Amy S., Weily Soong, Mark Boguniewicz, et al.. (2024). 548 - Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities. British Journal of Dermatology. 190(Supplement_2). ii46–ii47. 1 indexed citations
7.
Paller, Amy S., Bob Geng, Alan D. Irvine, et al.. (2024). 51363 Growth Analysis in Children Aged Less Than 12 Years with Moderate-to-Severe Atopic Dermatitis. Journal of the American Academy of Dermatology. 91(3). AB1–AB1. 1 indexed citations
8.
Paller, Amy S., Weily Soong, Mark Boguniewicz, et al.. (2024). Tralokinumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 years and Older With and Without Atopic Comorbidities. SKIN The Journal of Cutaneous Medicine. 8(1). s322–s322. 1 indexed citations
9.
10.
Lee, Stephanie J., et al.. (2022). Atopic dermatitisReview of comorbidities and therapeutics. Annals of Allergy Asthma & Immunology. 129(2). 142–149. 7 indexed citations
11.
Bertrand, Kerri, Christina Chambers, Anthony J. O’Donoghue, et al.. (2022). Allergen Content and Protease Activity in Milk Feeds from Mothers of Preterm Infants. Breastfeeding Medicine. 17(11). 947–957. 1 indexed citations
12.
Geng, Bob, Claus Bachert, William W. Busse, et al.. (2021). Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. The Journal of Allergy and Clinical Immunology In Practice. 10(3). 732–741. 22 indexed citations
13.
Geng, Bob & Timothy Craig. (2021). Small molecule drugs for atopic dermatitis, rheumatoid arthritis, and hereditary angioedema. Annals of Allergy Asthma & Immunology. 128(3). 263–268. 5 indexed citations
14.
Geng, Bob, et al.. (2020). Intravenous versus Subcutaneous Immunoglobulin in Primary Immunodeficiency: Real-World Evaluation of Safety, Efficacy, and Patient Perceptions. Journal of Clinical & Cellular Immunology. 11(3). 1–11. 1 indexed citations
15.
Geng, Bob, Sydney Leibel, Praveen Akuthota, et al.. (2020). Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab. The Journal of Allergy and Clinical Immunology In Practice. 8(10). 3643–3646.e1. 11 indexed citations
16.
Kobayashi, Roger H., Sudhir Gupta, Isaac Melamed, et al.. (2019). Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies. Frontiers in Immunology. 10. 40–40. 15 indexed citations
17.
Berger, Melvin, et al.. (2017). Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease. Respiratory Medicine. 132. 181–188. 39 indexed citations
18.
Geng, Bob, et al.. (2015). Factors associated with negative histamine control for penicillin allergy skin testing in the inpatient setting. Annals of Allergy Asthma & Immunology. 115(1). 33–38. 12 indexed citations
19.
Geng, Bob, et al.. (2014). Successful stem cell transplantation in Chediak-Higashi syndrome. The Journal of Allergy and Clinical Immunology In Practice. 3(2). 271–272. 1 indexed citations
20.
Wang, Yen Tun, Bob Geng, Maria Garcia-Lloret, et al.. (2013). Cutaneous Granulomas and Epidermodysplasia Verruciformis in Early Onset Combined Immunodeficiency Syndrome. American Journal of Dermatopathology. 36(2). 179–183. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Denisa Ferastraoaru Breakdown of academic impact, for papers by Andrew J. MacGinnitie Breakdown of academic impact, for papers by Rémi Gagnon Breakdown of academic impact, for papers by Saira Z. Sheikh Breakdown of academic impact, for papers by Francesca Saretta Breakdown of academic impact, for papers by Ramit Maoz‐Segal Breakdown of academic impact, for papers by B Z Garty Breakdown of academic impact, for papers by Ori Toker Breakdown of academic impact, for papers by Giacomo Malipiero Breakdown of academic impact, for papers by Inderpal Randhawa
Rankless by CCL
2026